MKI67 and diffuse large B-cell lymphoma: Further, analysis of the Ki-67+ proliferative area of MD-901 ABC-DLBCL tumor xenografts revealed that only miR-28+ibrutinib combination therapy significantly reduced proliferation (Fig. 4C).